Pulmonary Arterial Hypertension (PAH) is a heterogenic 
group of devastating disorders that characterizes higher rates of 
mortality and morbidity worldwide. Recent clinical studies have 
shown that clinical features, hemodynamic parameters, 
echocardiography patter, multi-spiral computer tomography 
findings, exercise capacity, and anti-nuclear antibody profiles 
could be used as predictors of clinical severity and outcomes in 
PAH patients. However, the reliability, sensitivity, specificity and 
predictive value are derived from PAH patients with different 
comorbidities and specific complications associated with CTD, 
congenital heart disease and respiratory disease might be 
unacceptable. The aim of the review: to summarize the 
knowledge regarding predictive value of several biomarkers in 
PAH individuals. The review is argued the perspective to utilize 
single sample and serial measurements of biomarkers as a 
regulatory peptide contributed in PAH pathogenesis aimed to 
improve prediction of PAH development and progression.